A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.

Br J Cancer · 2006 · PMC2360568 · PMID 17031397

Europe PMC DOI

hedged sentence

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

showed a trendP =0.097so close (0.05 < p ≤ 0.1)

Temsirolimus effectively inhibited the phosphorylation of S6 ( P =0.02) ( Figure 4 ) and higher baseline levels of pS6 showed a trend towards being predictive of a better response ( P =0.097).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.